Last Friday at the close, shares in Gaithersburg, Maryland headquartered Novavax Inc. ended 1.53% lower at $1.29 with a total trading volume of 6.39 million shares. The stock is trading below its 50-day moving average by 44.18%. Shares of the Company, which focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants, have a Relative Strength Index (RSI) of 38.53.
As per notes filed with the SEC on November 16th, 2016, the Compensation Committee of Novavax's Board of Dsirectors approved a form of incentive stock option agreement, which may be used for awards made under the Company's 2015 Stock Incentive Plan, as amended. The Form Incentive Stock Option Agreement provides for the grant of options to purchase the Company's common stock, subject to the performance- and time-based vesting conditions to be set forth in the applicable agreement. Sign up and read the free research report on NVAX at:
Foster City, California headquartered Gilead Sciences Inc.'s stock finished Friday's session 1.27% lower at $74.62 and with a total trading volume of 8.17 million shares. The Company's shares have advanced 0.42% in the last month. The stock is trading below its 50-day moving average by 2.17%. Additionally, shares of Gilead Sciences, which discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia/Pacific, have an RSI of 44.52.
On November 14th, 2016, research firm Stifel initiated a 'Buy' rating on the Company's stock, issuing a target price of $100 per share.
On November 16th, 2016, Gilead Sciences announced top-line results from two Phase 3 clinical trials evaluating momelotinib, an investigational inhibitor of Janus kinase compared to ruxolitinib or best alternative therapy in patients with myelofibrosis. The SIMPLIFY-1 study achieved its pre-specified primary endpoint of non-inferiority to ruxolitinib for splenic response rate at Week 24, defined as the percentage of patients experiencing a ≥ 35% reduction in spleen volume. The complimentary research report on GILD can be downloaded at:
Shares in Massachusetts headquartered Ariad Pharmaceuticals Inc. ended the session 1.22% higher at $14.06 and with a total trading volume of 6.02 million shares. The stock has surged 30.43% in the past month, 33.14% in the previous three months, and 124.96% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 20.04% and 62.99%, respectively. Moreover, shares of Ariad Pharma, which engages in the discovery, development, and commercialization of drugs for cancer patients in the US and internationally, have an RSI of 69.50.
On November 03rd, 2016, research firm Deutsche Bank initiated a 'Hold' rating on the Company's stock, issuing a target price of $9.50 per share.
On November 16th, 2016, ARIAD Pharmaceuticals announced that clinical data on brigatinib, its investigational anaplastic lymphoma kinase inhibitor, will be presented at the International Association for the Study of Lung Cancer 17th World Conference on Lung Cancer being held in Vienna, December 4th to 7th, 2016. "ALTA data to be presented at the meeting will include approximately three months of additional follow-up as compared to the abstract," stated Timothy P. Clackson, Ph.D., president of research and development and chief scientific officer at ARIAD. Register for free on Stock-Callers.com and access the latest report on ARIA at:
South San Francisco, California headquartered Exelixis Inc.'s stock recorded a trading volume of 6.56 million shares, and closed 1.25% higher at $16.96. The Company's shares have gained 44.46% in the past month, 48.25% over the previous three months, and 200.71% since the start of this year. The stock is trading 30.55% above its 50-day moving average and 106.26% above its 200-day moving average. Additionally, shares of Exelixis, which engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer, have an RSI of 74.42.
On November 03rd, 2016, Exelixis reported Q3 2016 total revenues were $62.2 million, compared to $9.9 million for Q3 2015. The company's net loss for Q3 2016 was ($11.3) million, or ($0.04) per share, compared to ($45.5) million, or ($0.21) per share, for Q3 2015.
On November 03rd, 2016, research firm Deutsche Bank initiated a 'Buy' rating on the Company's stock, issuing a target price of $17 per share. Get free access to your research report on EXEL at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices,Second Floor, 48 West George Street,Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA